GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
A placebo-controlled, multicenter, randomized trial to test GKT137831 in ambulatory patients
with idiopathic pulmonary fibrosis. This drug is an inhibitor of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. The investigators hypothesize the drug
will decrease pulmonary injury due to reactive oxygen species (ROS) generated by NOX enzymes,
which are believed to play an important role in the development of IPF. Treatment with
GKT137831 could result in significant benefit for a lung disease that has, until now, been
almost invariably inexorable.
This clinical trial represents the bedside application of a series of NOX translational and
basic studies and discoveries, over several years, from the laboratory of Dr. Victor
Thannickal.